Effects of ziprasidone and olanzapine on body composition and metabolic parameters: an open-label comparative pilot study

Table 1 Body weight, body composition, and appetite of ziprasidone- and olanzapine-treated patients (n = 10 per group)

	Ziprasidone start	Ziprasidone end		Olanzapine start	Olanzapine end		Ziprasidone change (%)^a	Olanzapine change (%)^a
Measure	Median (IQR)	Median (IQR)	P^b	Median (IQR)	Median (IQR)	P^b	Median (IQR)	Median (IQR)	P^c
BW(kg)	58.75 (54.28, 61.68)	60.85 (56.40, 67.88)	0.168	57.70 (51.25, 65.90)	65.70 (56.73, 72.88)	0.005^*	3.43 (0.61, 9.20)	10.35 (9.27, 14.65)	0.016^*
BMI (kg/m²)	21.50 (19.20, 24.00)	22.35 (19.48, 25.18)	0.139	21.85 (17.90, 23.65)	23.95 (20.35, 26.53)	0.005^*	4.09 (0.55, 10.20)	10.93 (9.02, 15.08)	0.019^*
Waist to hip ratio	0.86 (0.83, 0.91)	0.84 (0.82, 0.94)	0.916	0.85 (0.81, 0.88)	0.87 (0.85, 0.93)	0.005^*	0.00 (−0.01, 0.02)	3.62 (2.16, 5.10)	0.004^*
LBM (kg)	44.65 (38.13, 48.30)	46.35 (42.48, 51.20)	0.028^*	44.35 (40.23, 54.30)	47.70 (41.63, 54.25)	0.074	3.05 (1.36, 9.71)	3.78 (−2.41, 11.53)	0.821
Muscle mass (kg)	41.90 (35.80, 45.68)	43.55 (39.88, 49.00)	0.028^*	41.75 (37.95, 51.55)	43.80 (39.20, 51.50)	0.074	3.01 (0.53, 9.67)	3.90 (−2.50, 7.40)	0.762
Fat mass (kg)	17.05 (7.58-21.88)	14.65 (8.40, 23.23)	0.721	13.00 (10.15, 15.73)	17.70 (12.05, 20.33)	0.017^*	7.84 (−12.34, 28.88)	31.57 (20.15, 56.03)	0.049^*
Appetite	5.00 (4.31, 6.44)	5.00 (3.38, 5.31)	0.212	5.00 (4.19, 5.25)	5.00 (4.69, 6.13)	0.399	−20.0 (−29.80, 5.00)	0.00 (−6.25, 39.34)	0.059

IQR Interquartile Range, BW Body Weight, BMI Body Mass Index, LBM, LBM.
^a, $\frac{(posttreatment - baseline)}{baseline}$ * 100; ^b,Wilcoxon signed rank test; ^c, Kruskal-Wallis H test; ^*, p < 0.05.